Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitor (ICI) plus anlotinib as third-line treatment in extensive-stage small cell lung cancer (ES-SCLC). Methods A total of 120 patients with ES-SCLC
Autor:
Christoph Röcken, HM Behrens, F. W. Schäfer, L.-J. Kramp, M. van Mackelenbergh, Micaela Mathiak
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background We explored the hypothesis that high-quality standards in diagnostic mammography can lead to an early diagnosis of breast cancers and identifies at risk populations outside screening programs. The histopathological features and distributio
Autor:
Alex Federico, Francesco Legge, Francesco Fanfani, Giovanni Scambia, Francesca Ciccarone, Martina Arcieri, Francesco Cosentino, Enrico Vizza, Luigi Carlo Turco, Camilla Certelli, Andrea Rosati, Gabriella Ferrandina, Giacomo Corrado
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Objective The aim of this retrospective study was to compare surgical and survival outcome in only patients with early-stage UCSs managed by laparotomic surgery (LPT) versus minimally invasive surgery (MIS). Methods Data were retrospectively collecte
Autor:
Lara Bußmann, Bjoern P. Schoennagel, Eric Bibiza, Stefan Bartels, Steffen Knopke, Christian Stephan Betz, Adrian Münscher, Nikolaus Möckelmann, Arne Böttcher, Chia-Jung Busch
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Controversies exist in regard to surgical neck management in total laryngectomies (TL). International guidelines do not sufficiently discriminate neck sides and sublevels, or minimal neck-dissection nodal yield (NY). Methods Thirty-seven cons
Autor:
Simon Fietz, Anne Fröhlich, Judith Sirokay, Andrea Buchner, Eva Egger, Jennifer Landsberg, Dennis Niebel
Publikováno v:
Cancer Immunology, Immunotherapy
Background Resistance to immune checkpoint blockade and targeted therapy in melanoma patients is currently one of the major clinical challenges. With the approval of talimogene laherparepvec (T-VEC), oncolytic viruses are now in clinical practice for
Autor:
Fumio Nagashima, Takayasu Kurata, Kazuhiko Nakagawa, Junji Furuse, Tsutomu Iwasa, Toshio Shimizu, Naohiro Okano, Yasuhito Fujisaka, Hiroshi Kitamura, Daisuke Naruge
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Patients with RAS-positive tumors respond poorly to chemotherapies and have a few treatment options. Salirasib is an oral RAS inhibitor that competitively blocks the membrane association of RAS proteins. The aim of this phase I multiple-ascen
Autor:
Atsuko Yamada, Kazuhiro Yoshida, Tatsuhiko Miyazaki, Nobuhisa Matsuhashi, Toshiyuki Tanahashi, Kazuya Yamaguchi, Yoshihiro Tanaka, Naoki Okumura
Publikováno v:
Cancer Chemotherapy and Pharmacology
The prognosis of esophageal cancer patients is still unsatisfactory. Although a docetaxel, cisplatin, and 5-Fu (DCF) regimen has been reported, it is often difficult to accomplish because of severe toxicity. Therefore, we developed a new biweekly DCF
Autor:
M. Gerstenhauer, Elisabeth C Inwald, Monika Klinkhammer-Schalke, Oliver Treeck, Patricia Lindberg, Ferdinand Hofstädter, Olaf Ortmann, Florian Zeman, Michael Koller, S. Schüler
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Adjuvant endocrine therapy (ET) is indicated in patients with steroid hormone receptor (HR)-positive breast cancer. The aim of this study was to evaluate the quality of HR determination and adjuvant endocrine treatment of breast cancer patien
Autor:
Mccann, Katy J., Godeseth, Rosemary, Chudley, Lindsey, Mander, Ann, Di Genova, Gianfranco, Lloyd-Evans, Paul, Kerr, Jonathan P., Malykh, Vladimir B., Jenner, Matthew W., Orchard, Kim H, Stevenson, Freda K., Ottensmeier, Christian H.
Publikováno v:
Cancer Immunology, Immunotherapy
We report on the safety and immunogenicity of idiotypic DNA vaccination in a phase I, non-randomised, open-label study in patients with multiple myeloma. The study used DNA fusion gene vaccines encoding patient-specific single chain variable fragment
Autor:
Sun Young Kyung, Hee Kyung Ahn, Dong Bok Shin, Sun Jin Sym, Eun Kyung Cho, Jeong-Woong Park, Sung Hwan Jeong, Minkyu Jung, Shin Myung Kang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Genexol-PM is a Cremorphor EL (CrEL)-free polymeric micelle formulation of paclitaxel that allows higher-dose administration with less hypersensitivity. This study was designed to evaluate the efficacy and safety of Genexol-PM and gemcitabine